Nelfinavir-mediated reduction in vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1α (HIF1α) through inhibition of the PI3K–Akt pathway has been observed by Pore et al. in head and neck carcinoma, lung cancer, and glioblastoma cells which contributed in reduced angiogenesis and potentiation of radiotherapy [103,104]. The gene discussed is VEGFA; the disease is head and neck carcinoma.